Today: The Honeywell International Inc. decreases its position in Merck & Co. (MRK)

The Honeywell International Inc. decreases its position in Merck & Co. (MRK)

Honeywell International Inc. reduced its stake in shares of Merck & Co. (NYSE:MRK) by 48.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 250,000 shares of the company’s stock after selling 235,100 shares during the period. Honeywell International Inc.’s holdings in Merck & Co. were worth $14,403,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Accredited Investors Inc. boosted its stake in Merck & Co. by 0.3% in the first quarter. Accredited Investors Inc. now owns 9,125 shares of the company’s stock valued at $483,000 after buying an additional 23 shares during the period. Thomaspartners Inc. boosted its stake in Merck & Co. by 0.3% in the first quarter. Thomaspartners Inc. now owns 9,024 shares of the company’s stock valued at $477,000 after buying an additional 26 shares during the period. QCI Asset Management Inc. NY boosted its stake in Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock valued at $137,000 after buying an additional 27 shares during the period. Vicus Capital boosted its stake in Merck & Co. by 0.3% in the first quarter. Vicus Capital now owns 11,121 shares of the company’s stock valued at $588,000 after buying an additional 37 shares during the period. Finally, Gerber Kawasaki Wealth & Investment Management boosted its stake in Merck & Co. by 0.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 4,738 shares of the company’s stock valued at $250,000 after buying an additional 39 shares during the period. 72.93% of the stock is owned by institutional investors.

Merck & Co. (NYSE:MRK) traded down 0.73% during midday trading on Friday, hitting $62.20. 4,770,241 shares of the stock traded hands. The firm has a market cap of $172.00 billion, a PE ratio of 34.12 and a beta of 0.68. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $64.00. The stock has a 50-day moving average of $62.69 and a 200 day moving average of $58.33.

Merck & Co. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 29th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.91 by $0.02. The company earned $9.84 billion during the quarter, compared to analyst estimates of $9.79 billion. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.86 EPS. Equities analysts forecast that Merck & Co. will post $3.75 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Tuesday, September 13th. Merck & Co.’s payout ratio is 101.10%.

Several research analysts have recently issued reports on the company. BMO Capital Markets lowered Merck & Co. from an “outperform” rating to a “market perform” rating and set a $62.00 price target on the stock. in a research report on Monday, July 18th. They noted that the move was a valuation call. Sanford C. Bernstein restated an “outperform” rating and issued a $74.00 price target (up from $66.00) on shares of Merck & Co. in a research report on Thursday, August 11th. Piper Jaffray Cos. restated a “neutral” rating and issued a $62.00 price target (up from $58.00) on shares of Merck & Co. in a research report on Monday, August 8th. Credit Suisse Group AG restated a “hold” rating and issued a $59.00 price target on shares of Merck & Co. in a research report on Wednesday, July 13th. Finally, Jefferies Group reduced their price target on Merck & Co. from $54.00 to $53.00 and set a “hold” rating on the stock in a research report on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of €63.20 ($70.23).

In other news, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares of the company’s stock, valued at €47,029,807.37 ($52,255,341.52). The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the sale, the insider now directly owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.

Merck & Co. Company Profile

Related posts

Leave a Comment